Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Europe Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Mar 2021 | Europe | 350 Pages | No of Tables: 151 | No of Figures: 36

Report Description

Europe Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Belgium, Rest of Europe) Industry Trends and Forecast to 2028.  

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights:  Europe Primary Angle-Closure Glaucoma Market

The primary angle-closure glaucoma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.1% in the forecast period of 2021 to 2028. Increasing prevalence of angle-closure glaucoma and advancement in surgical treatment of the disease are the key drivers for primary angle-closure glaucoma market.

Glaucoma is a group of eye conditions that damage the optic nerve and the proper functioning of the optic nerve is necessary for good vision. This damage is often caused by abnormally high pressure in the eye. The primary angle-closure (PAC) is defined as appositional or synechial closure of the anterior chamber angle which can lead to aqueous outflow obstruction and raised IOP in the absence of glaucomatous optic neuropathy.

The increasing population of women and greater female to male ratio in angle-closure glaucoma due to various anatomical and hormonal factors showed the prevalence of the disease in women with increasing women population which is expected to drive the primary angle-closure glaucoma market in the forecasted period. The poor reimbursements are seen as a restraint for the primary angle-closure glaucoma market. The governing body for the approval of products has a significant role in the primary angle-closure glaucoma market growth. The increasing approval of the product for the primary angle-closure glaucoma is expected to boost the market in the forecasted period and will act as opportunities for the primary angle-closure glaucoma market growth. The risks associated with the micro-invasive glaucoma surgery acts as a challenge for the primary angle-closure glaucoma market.

The primary angle closure glaucoma market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

Get Exclusive Sample Copy of this Report Here

Global Primary Angle-Closure Glaucoma Market Scope and Market Size 

The primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma. In 2021, acute angle-closure glaucoma segment is dominating in the primary angle-closure glaucoma market owing to the high incidence cases for acute cases.
  • On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment. In 2021, diagnosis segment is dominating in the primary angle-closure glaucoma market due to the primary test and secondary testing options available for the diagnosis and physicians after a proper diagnosis only prefer the medical procedure.
  • On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers and others. In 2021, hospitals segment is dominating the primary angle-closure glaucoma market as this segment is specialized in conducting various surgical interventions and has a large professional’s portfolio available for giving the proper treatment.
  • On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others. In 2021, direct tender segment dominates the primary angle-closure glaucoma market as they are the primary source of procurement of diagnostic and surgical devices by healthcare organizations and specialty clinics.

Primary Angle-Closure Glaucoma Market Country Level Analysis

The primary angle-closure glaucoma market is analysed and market size information is provided by the country, disease type, type, end user and distribution channel as referenced above.

The countries covered in the Europe primary angle-closure glaucoma market report are the Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Belgium, and Rest of Europe.  

Europe is expected to grow with the highest CAGR in the forecasted period due to the growing demand of secondary hyperoxaluria. Germany is expected to dominate in the market in the market as Germany is one of the leading countries which have huge market potential.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Incidence in Emerging Market and Rapid Transition from PACG medication to Surgeries are Creating New Opportunities for Players in the Primary Angle-Closure Glaucoma Market

Primary angle-closure glaucoma market also provides you with detailed market analysis for every country growth in particular industry with angle-closure glaucoma surgical and diagnosis product sales, impact of advancement in the primary angle-closure glaucoma and changes in regulatory scenarios with their support for the primary angle-closure glaucoma Market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Primary Angle-Closure Glaucoma Market Share Analysis

The primary angle-closure glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to primary angle-closure glaucoma market.

The major companies dealing in the primary angle-closure glaucoma market report are Johnson & Johnson Vision Care, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), NIDEK CO., LTD, BVI, Allergan (a subsidiary of AbbVie Inc.), Bausch & Lomb Incorporated (A Subsidiary of Bausch Health Companies Inc.), Oertli Instrumente AG, Nova Eye Medical Limited, ZEISS International, Alcon Inc., Reichert, Inc. (A Business Unit of Ametek.Inc.), NEW VISION among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the primary angle-closure glaucoma market.

For instance,

  • In June 2020, Oertli Instrumente AG announced that they had opened the YouTube Channel in which they will provide knowledge about glaucoma and cataract and showcase their product. This is great initiative by the company to come in a social media platform which will increase the reach of the company and increase their demand.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the primary angle-closure glaucoma which also provides the benefits for organisations to improve their offerings for primary angle-closure glaucoma market.   


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EPIDEMIOLOGY

5 REGULATORY FRAMEWORK

6 PIPELINE ANALYSIS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA

7.1.2 INCREASING WOMEN POPULATION

7.1.3 RISE IN GERIATRIC POPULATION

7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE

7.1.5 INCREASED ECONOMIC BURDEN

7.2 RESTRAINTS

7.2.1 HIGH SURGICAL COSTS OF PACG

7.2.2 INADEQUATE REIMBURSEMENT SCENARIO

7.2.3 DELAYED AND MISDIAGNOSIS OF PACG

7.3 OPPORTUNITIES

7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA

7.3.2 RECENT APPROVAL BY GOVERNING BODIES

7.3.3 INCREASING INCIDENCES IN EMERGING MARKET

7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES

7.4 CHALLENGES

7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES

7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE

7.4.3 LIMITED ACCESS TO TREATMENT

8 IMPACT OF COVID-19 ON EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISION BY MANUFACTURERS

8.5 CONCLUSION

9 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET

9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET

10 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE

10.1 OVERVIEW

10.2 DIAGNOSIS

10.2.1 PRIMARY TEST

10.2.1.1 GONIOSCOPY EXAMINATION

10.2.1.2 SLIT-LAMP EXAMINATION

10.2.1.3 AUTOMATIC STATIC PERIMETRY

10.2.2 SECONDARY TEST

10.2.2.1 ULTRASOUND BIOMICROSCOPY

10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT)

10.2.2.3 RETINAL OCT

10.2.2.4 FUNDOSCOPY

10.2.2.5 OTHERS

10.3 TREATMENT

10.3.1 SURGICAL IRIDECTOMY

10.3.2 TRABECULECTOMY

10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS)

10.3.4 GONIOTOMY

10.3.5 OTHERS

11 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 AMBULATORY SURGICAL CENTERS

11.4 SPECIALTY CLINICS

11.5 OTHERS

12 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 OTHERS

13 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY

13.1 EUROPE

13.1.1 GERMANY

13.1.2 FRANCE

13.1.3 ITALY

13.1.4 U.K.

13.1.5 SPAIN

13.1.6 RUSSIA

13.1.7 AUSTRIA

13.1.8 NETHERLANDS

13.1.9 HUNGARY

13.1.10 POLAND

13.1.11 SWITZERLAND

13.1.12 TURKEY

13.1.13 NORWAY

13.1.14 LITHUANIA

13.1.15 IRELAND

13.1.16 REST OF EUROPE

14 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 SWOT

16 COMPANY PROFILES

16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 ALCON INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 ZEISS INTERNATIONAL

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 NOVA EYE MEDICAL LIMITED

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 NIDEK CO., LTD

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 APPASAMY ASSOCIATES

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 AUROLAB

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 BVI

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENTS

16.11 LIGHTMED

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 LUNEAU TECHNOLOGY USA

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 MEDISONIC EQUIPMENTS PVT. LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 MICROSURGICAL TECHNOLOGY

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENTS

16.15 NEW VISION

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENTS

16.16 NEW WORLD MEDICAL, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 OERTLI INSTRUMENTE AG

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 OMNI LENS

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.)

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENTS

16.2 SIGHT SCIENCES, INC.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, PIPELINE ANALYSIS

TABLE 2 NUMBER OF OPHTHALMOLOGISTS/MILLION POPULATIONS

TABLE 3 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 EUROPE ACUTE-ANGLE CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 EUROPE CHRONIC ANGLE-CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET,BY REGION, 2019-2028 (USD MILLION)

TABLE 6 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 7 EUROPE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 EUROPE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 9 EUROPE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 10 EUROPE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 11 EUROPE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 2019-2028 (USD MILLION)

TABLE 12 EUROPE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 13 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 14 EUROPE HOSPITALS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 15 EUROPE AMBULATORY SURGICAL CENTERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 16 EUROPE SPECIALTY CLINICS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 17 EUROPE OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 18 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 19 EUROPE DIRECT TENDER IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 20 EUROPE RETAIL SALES IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 21 EUROPE OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 22 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 23 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 24 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 25 EUROPE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 26 EUROPE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 27 EUROPE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 28 EUROPE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 29 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 30 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 31 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 32 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 33 GERMANY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 34 GERMANY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 35 GERMANY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 36 GERMANY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 37 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 40 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 41 FRANCE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 42 FRANCE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 43 FRANCE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 44 FRANCE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 45 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 47 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 48 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 49 ITALY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 50 ITALY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 51 ITALY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 52 ITALY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 53 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 56 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 57 U.K. DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 58 U.K. PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 59 U.K. SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 60 U.K. TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 61 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 62 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 63 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 64 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 65 SPAIN DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 66 SPAIN PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 67 SPAIN SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 68 SPAIN TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 69 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 70 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 71 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 72 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 73 RUSSIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 74 RUSSIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 75 RUSSIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 76 RUSSIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 77 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 78 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 79 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 80 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 81 AUSTRIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 82 AUSTRIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 83 AUSTRIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 84 AUSTRIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 85 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 86 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 87 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 88 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 89 NETHERLANDS DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 90 NETHERLANDS PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 91 NETHERLANDS SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 92 NETHERLANDS TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 93 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 97 HUNGARY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 98 HUNGARY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 99 HUNGARY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 100 HUNGARY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 101 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 102 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 103 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 104 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 105 POLAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 106 POLAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 107 POLAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 108 POLAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 109 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 110 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 111 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 112 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 113 SWITZERLAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 114 SWITZERLAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 115 SWITZERLAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 116 SWITZERLAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 117 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 118 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 119 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 120 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 121 TURKEY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 122 TURKEY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 123 TURKEY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 124 TURKEY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 125 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 126 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 127 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 128 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 129 NORWAY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 130 NORWAY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 131 NORWAY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 132 NORWAY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 133 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 134 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 135 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 136 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 137 LITHUANIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 138 LITHUANIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 139 LITHUANIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 140 LITHUANIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 141 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 142 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 143 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 144 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 145 IRELAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 146 IRELAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 147 IRELAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 148 IRELAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 149 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 150 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 151 REST OF EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 2 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

FIGURE 15 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020

FIGURE 16 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 19 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 20 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)

FIGURE 21 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020

FIGURE 24 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 25 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 26 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE

FIGURE 27 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 28 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 29 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 30 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 31 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)

FIGURE 32 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)

FIGURE 33 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)

FIGURE 34 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)

FIGURE 35 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)

FIGURE 36 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)

View Infographics

FIGURE 1 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 2 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

FIGURE 15 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020

FIGURE 16 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 EUROPE PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 19 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 20 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)

FIGURE 21 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020

FIGURE 24 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 25 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 26 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE

FIGURE 27 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 28 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 29 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 30 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 31 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)

FIGURE 32 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)

FIGURE 33 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)

FIGURE 34 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)

FIGURE 35 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)

FIGURE 36 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19